UA104741C2 - Моноклональні антитіла проти феропортину 1 та варіанти їх застосування - Google Patents

Моноклональні антитіла проти феропортину 1 та варіанти їх застосування

Info

Publication number
UA104741C2
UA104741C2 UAA201107028A UAA201107028A UA104741C2 UA 104741 C2 UA104741 C2 UA 104741C2 UA A201107028 A UAA201107028 A UA A201107028A UA A201107028 A UAA201107028 A UA A201107028A UA 104741 C2 UA104741 C2 UA 104741C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibodies
ferroportin
maintaining
increasing
iron
Prior art date
Application number
UAA201107028A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Донмайєнн Дон Мун Льюнг
Пен Луань
Джозеф Вінсент Манетта
Їнь Тань
Деррік Райан Уітчер
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA104741C2 publication Critical patent/UA104741C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201107028A 2008-12-05 2009-12-01 Моноклональні антитіла проти феропортину 1 та варіанти їх застосування UA104741C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US23981809P 2009-09-04 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA104741C2 true UA104741C2 (uk) 2014-03-11

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201107028A UA104741C2 (uk) 2008-12-05 2009-12-01 Моноклональні антитіла проти феропортину 1 та варіанти їх застосування

Country Status (25)

Country Link
EP (1) EP2373335B1 (https=)
JP (1) JP5713917B2 (https=)
KR (1) KR101353117B1 (https=)
CN (1) CN102238962B (https=)
AR (1) AR074398A1 (https=)
AU (1) AU2009322587B2 (https=)
BR (1) BRPI0922288A2 (https=)
CA (1) CA2745618C (https=)
CY (1) CY1117355T1 (https=)
DK (1) DK2373335T3 (https=)
EA (1) EA020472B1 (https=)
ES (1) ES2566343T3 (https=)
HR (1) HRP20160302T1 (https=)
HU (1) HUE028585T2 (https=)
IL (1) IL212731A0 (https=)
MX (1) MX2011005939A (https=)
NZ (1) NZ592545A (https=)
PA (1) PA8849601A1 (https=)
PL (1) PL2373335T3 (https=)
SG (1) SG171960A1 (https=)
SI (1) SI2373335T1 (https=)
TW (1) TW201023891A (https=)
UA (1) UA104741C2 (https=)
WO (1) WO2010065496A1 (https=)
ZA (1) ZA201103941B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014013806A (es) * 2012-05-14 2014-11-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
WO2009094551A1 (en) * 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use

Also Published As

Publication number Publication date
PA8849601A1 (es) 2010-07-27
EA201170764A1 (ru) 2011-12-30
MX2011005939A (es) 2011-06-27
HUE028585T2 (en) 2016-12-28
JP5713917B2 (ja) 2015-05-07
CY1117355T1 (el) 2017-04-26
EA020472B1 (ru) 2014-11-28
IL212731A0 (en) 2011-07-31
AR074398A1 (es) 2011-01-12
WO2010065496A1 (en) 2010-06-10
CA2745618A1 (en) 2010-06-10
BRPI0922288A2 (pt) 2018-08-28
HK1158977A1 (zh) 2012-07-27
EP2373335B1 (en) 2016-02-24
SI2373335T1 (sl) 2016-04-29
PL2373335T3 (pl) 2016-08-31
JP2012510814A (ja) 2012-05-17
NZ592545A (en) 2012-12-21
SG171960A1 (en) 2011-07-28
TW201023891A (en) 2010-07-01
KR20110084996A (ko) 2011-07-26
EP2373335A1 (en) 2011-10-12
CA2745618C (en) 2014-06-10
AU2009322587B2 (en) 2013-09-26
HRP20160302T1 (hr) 2016-04-22
KR101353117B1 (ko) 2014-02-17
ES2566343T3 (es) 2016-04-12
AU2009322587A1 (en) 2011-07-28
DK2373335T3 (en) 2016-05-02
ZA201103941B (en) 2012-11-28
CN102238962B (zh) 2014-02-12
CN102238962A (zh) 2011-11-09

Similar Documents

Publication Publication Date Title
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
MX343747B (es) Agentes de union diana contra b7-h1.
UA104741C2 (uk) Моноклональні антитіла проти феропортину 1 та варіанти їх застосування
WO2011126833A3 (en) Anti-inflammatory factors
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
PH12013500826A1 (en) Means and methods for treating dlbcl
WO2005123779A3 (en) Antibodies binding to cd34+/cd36+ fetal but not to adult cells
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
EP2210939A4 (en) Anti-bst2 antibody
HK1199837A1 (en) Humanized antibodies to inkt
WO2013136189A3 (en) Methods and materials for treatment of pompe's disease
NZ609501A (en) Antibodies to notum pectinacetylesterase
MX2025001934A (es) UN ANTICUERPO HUMANIZADO QUE TIENE ESPECIFICIDAD DE UNIÓN PARA LA INTEGRINA A4ß7 HUMANA PARA USARSE EN LA PREVENCIÓN O REDUCCIÓN DE LA APARICIÓN DE GVHD AGUDA EN UN PACIENTE HUMANO QUE TIENE ALL O AML Y QUE SE SOMETE A ALLO-HSCT
NZ609567A (en) Markers of endothelial progenitor cells and uses thereof
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
WO2008135960A3 (en) A composition for increasing stamina
WO2012022734A3 (en) Anti-icam-1 antibodies and methods of use
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
HK1200355A1 (en) Treatment of red blood cells
Abou Ayache et al. Preemptive renal transplantation in adults
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
WO2013071038A3 (en) Antagonists for abnormal vasopressin v2 receptor and uses thereof